MG
BCYC

Marex Group’s Bicycle Therapeutics BCYC Stock Holding History

Marex Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-115,000
Closed -$534K – 1146
2026
Q1 		$534K Buy
115,000
+36,594
+47% +$209K ﹤0.01% 608
2025
Q4 		$555K Buy
+78,406
New +$578K ﹤0.01% 536

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Marex Group's BCYC Position: Q2 2026 in Review

Marex Group sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 115,000 shares — an estimated $534K sold.

Marex Group first reported a position in BCYC in Q4 2025 and held it in 2 quarters. The position peaked at $555K in Q4 2025. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Marex Group reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marex Group sold 115,000 Bicycle Therapeutics shares in Q2 2026, an estimated $534K.
  • Marex Group first reported a position in Bicycle Therapeutics in Q4 2025 and held it in 2 quarters.
  • Marex Group's Bicycle Therapeutics position peaked at $555K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.